Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fandosentan SCHEMBL29388301 | 1.00 | EDNRA (1.00) | EDNRALMNAAKR1C3AKR1C2FABP4 | |
| Fandosentan SCHEMBL7947757 | 0.99 | EDNRA (0.98) | EDNRALMNAAKR1C3AKR1C2FABP4 | |
| Fandosentan SCHEMBL7547479 | 0.99 | EDNRA (0.98) | EDNRALMNAAKR1C3AKR1C2FABP4 | |
| Fandosentan SCHEMBL6541919 | 0.99 | EDNRA (0.98) | EDNRALMNAAKR1C3AKR1C2FABP4 | |
| Fandosentan SCHEMBL29566018 | 0.92 | EDNRA (0.85) | EDNRALMNAAKR1C3AKR1C2FABP4 | |
| Fandosentan SCHEMBL6541921 | 0.92 | EDNRA (0.85) | EDNRALMNAAKR1C3AKR1C2FABP4 | |
| Fandosentan SCHEMBL7947761 | 0.92 | EDNRA (0.85) | EDNRALMNAAKR1C3AKR1C2FABP4 | |
| SCHEMBL6542463 | 0.91 | EDNRA (0.83) | EDNRALMNAAKR1C3AKR1C2ELANE | |
| SCHEMBL7985075 | 0.90 | EDNRA (0.82) | EDNRALMNAAKR1C3AKR1C2ELANE | |
| SCHEMBL6541350 | 0.88 | EDNRA (0.79) | EDNRALMNAFABP4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1009743-B1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER LAMBERT CO (US) | 2004-06-30 | — | — | EP | claimed |
| US-20030073684-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2003-04-17 | — | — | US | claimed |
| US-6440962-B2 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | claimed |
| US-20020115661-A1 | Method for treating chronic obstructive pulmonary disease | KELLER LAURENCE HARVEY (US) | 2002-08-22 | — | — | US | claimed |
| EP-1213019-A2 | Method for treating chronic obstructive pulmonary disease | WARNER-LAMBERT COMPANY (US) | 2002-06-12 | — | — | EP | claimed |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2001-11-01 | — | — | US | claimed |
| US-6265399-B1 | ALKYLATION; CYCLIZATION | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | claimed |
| US-6252070-B1 | REACTING ARYL BROMIDE WITH BUTYLLITHIUM AND ZINC BROMIDE TO GIVE ARYL ZINC BROMIDE; REACTING WITH CORRESPONDING BENZOTHIAZINE COMPOUND | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | claimed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-6440962-B2 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020115661-A1 | Method for treating chronic obstructive pulmonary disease | KELLER LAURENCE HARVEY (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2002-07-18 | — | — | US | disclosed |
| EP-1213019-A2 | Method for treating chronic obstructive pulmonary disease | WARNER-LAMBERT COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6265399-B1 | ALKYLATION; CYCLIZATION | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6252070-B1 | REACTING ARYL BROMIDE WITH BUTYLLITHIUM AND ZINC BROMIDE TO GIVE ARYL ZINC BROMIDE; REACTING WITH CORRESPONDING BENZOTHIAZINE COMPOUND | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRA 429/4885LMNA 1240/4885AKR1C3 1764/4885 |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | EDNRA 2/4885LMNA 2078/4885AKR1C3 1553/4885 |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | EDNRA 2/4885LMNA 2078/4885AKR1C3 1553/4885 |
| US-20020115661-A1 | Method for treating chronic obstructive pulmonary disease | EDNRA, EPX, EDNRB | EDNRA 1/4885LMNA 4565/4885AKR1C3 947/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRA 11/4885LMNA 865/4885AKR1C3 2262/4885 |
| US-20030073684-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | EDNRA 2/4885LMNA 2078/4885AKR1C3 1553/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885LMNA 1625/4885AKR1C3 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.